☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search category
Search here
Search here
Subscribe Now
Trodelvy
Insights+: EMA Marketing Authorization of New Drugs in July 2023
August 25, 2023
Gilead’s Trodelvy (sacituzumab govitecan) Receives EC’s Approval for Pre-Treated HR+/HER2- Metastatic Breast Cancer
July 28, 2023
Gilead Receives EMA’s CHMP Positive Opinion of Trodelvy (sacituzumab govitecan) for Pre-Treated HR+/HER2- Metastatic Breast Cancer
June 23, 2023
Gilead to Presents P-III (TROPiCS-02) Study Results of Trodelvy (sacituzumab govitecan) for Pre-Treated HR+/HER2- Metastatic Breas...
June 6, 2023
Gilead Reports EMA's Validation of MAA for Trodelvy (sacituzumab govitecan-hziy) to Treat HR+/HER2- Metastatic Breast Cancer
January 3, 2023
Gilead Reports the US FDA's Acceptance of Trodelvy's sBLA for Priority Review to Treat Pre-Treated HR+/HER2- Metastatic Breast Can...
October 12, 2022
Load more...
Back to Home